Cargando…

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

Cancer immunotherapy has evolved dramatically with improved understanding of immune microenvironment and immunosurveillance. The immunogenicity of breast cancer is rather heterogeneous. Specific subtypes of breast cancer such as estrogen receptor (ER)-negative, human EGF receptor 2 (HER2)-positive,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayoub, Nehad M, Al-Shami, Kamal M, Yaghan, Rami J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340364/ https://www.ncbi.nlm.nih.gov/pubmed/30697064 http://dx.doi.org/10.2147/BCTT.S175360

Ejemplares similares

A Proposal of a Clinically Based Classification for Idiopathic Granulomatous Mastitis
por: Yaghan, Rami, et al.
Publicado: (2019)

Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study
por: Ayoub, Nehad M, et al.
Publicado: (2021)

The Role of Establishing a Multidisciplinary Team for Idiopathic Granulomatous Mastitis in Improving Patient Outcomes and Spreading Awareness about Recent Disease Trends
por: Yaghan, Rami J., et al.
Publicado: (2020)

Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
por: Ayoub, Nehad M., et al.
Publicado: (2022)

Impact of Obesity on Clinicopathologic Characteristics and Disease Prognosis in Pre- and Postmenopausal Breast Cancer Patients: A Retrospective Institutional Study
por: Ayoub, Nehad M., et al.
Publicado: (2019)

Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
por: Palaia, Innocenza, et al.
Publicado: (2020)

Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents
por: Ayoub, Nehad M, et al.
Publicado: (2017)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo
por: Siddique, Abu Bakar, et al.
Publicado: (2019)

Immunotherapies against HER2-Positive Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2023)

Effectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer
por: Al-Muqbel, Kusai M., et al.
Publicado: (2016)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

Is there a role for immunotherapy in HER2-positive breast cancer?
por: Holgado, Esther, et al.
Publicado: (2018)

Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices
por: Schwartzberg, Lee, et al.
Publicado: (2020)

Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
por: Kahraman, Seda, et al.
Publicado: (2021)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2021)

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
por: Pous, Anna, et al.
Publicado: (2023)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
por: Arab, Atefeh, et al.
Publicado: (2020)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
por: Sirhan, Zaid, et al.
Publicado: (2022)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

Targeting HER2-positive breast cancer: advances and future directions
por: Swain, Sandra M., et al.
Publicado: (2022)

New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
por: Mezni, Essia, et al.
Publicado: (2020)

Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells
por: Valsesia-Wittmann, Sandrine, et al.
Publicado: (2013)

Recent advances in vaccine and immunotherapy for COVID-19
por: Rabaan, Ali A., et al.
Publicado: (2020)

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
por: Miles, David W
Publicado: (2009)

Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
por: Chuang, Jeremy, et al.
Publicado: (2022)

Editorial: Novel Combination Therapies for the Treatment of Solid Cancers
por: Ayoub, Nehad M.
Publicado: (2021)

Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
por: Qi, Xiaowei, et al.
Publicado: (2023)

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
por: Pernas, Sonia, et al.
Publicado: (2019)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Is laterality in breast Cancer still worth studying? Local experience in Bahrain
por: Al Saad, Suhair, et al.
Publicado: (2022)

Therapeutic siRNA for drug-resistant HER2-positive breast cancer
por: Gu, Shenda, et al.
Publicado: (2016)

Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia
por: Chen, Kent T. J., et al.
Publicado: (2019)

Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor–Positive Breast Cancer
por: Lee, Eunice Yoojin, et al.
Publicado: (2023)

Recent advances in cancer immunotherapy
por: Sun, Weijing
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_abuh71a7tmd4fbn5ana8pgp2as